Holen Sie sich die Stockscreener-App
76.13
0.72%
0.5666
Schlusskurs vom Vortag:
$75.56
Offen:
$76
24-Stunden-Volumen:
567.37K
Relative Volume:
0.28
Marktkapitalisierung:
$12.58B
Einnahmen:
$1.06B
Nettoeinkommen (Verlust:
$-326.58M
KGV:
-36.21
EPS:
-2.1022
Netto-Cashflow:
$-977.73M
1W Leistung:
+3.07%
1M Leistung:
+3.87%
6M Leistung:
-7.97%
1J Leistung:
+130.76%
1-Tages-Spanne:
$74.73
$76.74
1-Wochen-Bereich:
$73.97
$76.80
52-Wochen-Spanne:
$32.00
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
76.12 | 12.49B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
436.69 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.91 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.47 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.95 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.71 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-04-10 | Fortgesetzt | Raymond James | Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-10-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Hochstufung | Goldman | Sell → Neutral |
| 2025-09-03 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Wolfe Research reiterates Ionis Pharmaceuticals stock rating ahead of rival data - Investing.com
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts - inkl
Ionis Pharmaceuticals (IONS) Valuation Check After Biogen Releases Phase 2 CELIA Alzheimer’s Study Results - Sahm
Ionis Pharmaceuticals, Inc. (IONS): Investor Outlook Highlights 33.56% Potential Upside - DirectorsTalk Interviews
Understanding Momentum Shifts in (IONS) - Stock Traders Daily
IONS Q1 earnings & sales beat, stock rises on raised '26 view - MSN
Ionis Pharmaceuticals’ SWOT analysis: stock gains momentum on FDA approval - Investing.com Nigeria
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
Ionis Pharmaceuticals Inc : Citigroup Initiat - Moomoo
Ionis Rises As Diranersen Phase 2 Spurs Biogen Registrational Plans - simplywall.st
IONS Initiated Coverage by Citigroup -- Price Target Set at $115 - GuruFocus
Citi Initiates Coverage on Biotech Stocks: Ionis (IONS), Alnylam (ALNY), BioMarin (BMRN) - GuruFocus
Ionis Pharmaceuticals (IONS) Receives Bullish Target from Citi A - GuruFocus
J.P. Morgan Initiates Ionis Pharmaceuticals(IONS.US) With Buy Rating, Announces Target Price $115 - Moomoo
Ionis, Alnylam, BioMarin are new Buys at Citi (ALNY:NASDAQ) - Seeking Alpha
Ionis Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
IONS News | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
Ionis Pharmaceuticals touts $3B TRYNGOLZA opportunity, pipeline readouts at conference - MSN
Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment - GlobeNewswire Inc.
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Biotech Powerhouse with 35.77% Upside Potential - DirectorsTalk Interviews
Biogen posts mid-stage trial data for Alzheimer’s candidate developed with Ionis - MSN
Ionis Pharmaceuticals repriced drug ahead of key FDA decision, signals push into larger market - MSN
Insider Sell: Brett Monia Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Ionis Pharmaceuticals CEO Brett P. Monia sells $356,012 in shares By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals CEO Brett P. Monia sells $356,012 in shares - Investing.com
Ionis (NASDAQ: IONS) CEO sells 4,536 shares after option exercise - Stock Titan
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $105 to $115 - Moomoo
CCORF Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $110 - Moomoo
T. Rowe Price holds 6.16M IONS shares (NYSE: IONS) — 3.7% stake - Stock Titan
Needham Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $105 - Moomoo
Ionis validates ABL Bio’s Grabody-B to deliver RNA drugs to brainCHOSUNBIZ - Chosunbiz
Ionis Pharmaceuticals, Inc.Common Stock (NQ: IONS - FinancialContent
Biogen has seen enough — despite no dose response — to advance tau-directed therapy - FirstWord Pharma
Capital World Investors holds 12.8% of Ionis (NASDAQ: IONS) - Stock Titan
Biogen AD drug shows tau, cognition benefit, despite trial miss - BioWorld News
Number of shareholders of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS - TradingView
Biogen plans registrational study for Alzheimer’s drug diranersen - Investing.com UK
Ionis partner Biogen announces topline results from phase 2 Celia study of diranersen - marketscreener.com
Biogen plans registrational study for Alzheimer’s drug diranersen By Investing.com - Investing.com Canada
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease - ChartMill
Pinnacle Associates Ltd. Reduces Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
A Look At Ionis Pharmaceuticals (IONS) Valuation After Recent Share Price Moves - Yahoo Finance
Ionis gets FDA breakthrough therapy status for zilganersen - MSN
Avoiding Lag: Real-Time Signals in (IONS) Movement - Stock Traders Daily
Brett Monia sells 160,773 IONS shares (IONS) via Form 144 - Stock Titan
Oppenheimer Maintains an “Outperform Rating” on Pharmaceuticals, Inc. (IONS) - Yahoo Finance
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ionis Pharmaceuticals Inc-Aktie (IONS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LOSCALZO JOSEPH | Director |
May 04 '26 |
Option Exercise |
48.74 |
77,289 |
3,767,309 |
113,619 |
| LOSCALZO JOSEPH | Director |
May 04 '26 |
Sale |
75.06 |
77,289 |
5,801,226 |
36,330 |
| KLEIN JOSEPH III | Director |
May 01 '26 |
Option Exercise |
47.11 |
10,111 |
476,329 |
21,125 |
| KLEIN JOSEPH III | Director |
May 01 '26 |
Sale |
73.51 |
10,111 |
743,238 |
11,014 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):